Munjal Showa Regulatory Approval

Munjal Showa Other Announcement

Munjal Showa Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.

Munjal Showa Legal & Regulatory

Munjal Showa received a tax assessment notice from the Haryana Excise & Taxation Department totaling ₹3.27 Crore for assessment years 2008-09 to 2014-15.

Value

₹3.27 Cr

Munjal Showa Annual General Meeting

Munjal Showa Limited held its 41st Annual General Meeting on August 24, 2026. Shareholders considered five business items including adoption of financial statements and dividend approval.

Munjal Showa Q1 FY27 Results: Net Profit ₹11.2 Cr, Up 34.9% YoY

Munjal Showa Ltd reported revenue from operations of ₹347.5 Cr (+21.5% YoY) and net profit of ₹11.2 Cr (+34.9% YoY) for Q1 FY27.

Key figure

Net profit ₹11.2 Cr · +34.9% YoY

Munjal Showa Annual Report

Munjal Showa has filed its Annual Report for the fiscal year 2025-26, which includes the Notice for the 41st Annual General Meeting of shareholders.

Munjal Showa Annual General Meeting

Munjal Showa Limited has scheduled its 41st Annual General Meeting for August 24, 2026, via video conferencing. The agenda includes dividend declaration and director appointments.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.